Press Releases

Year

Oct 27, 2020

Allogene Therapeutics to Report Third Quarter 2020 Financial Results on November 4, 2020

Conference Call and Webcast Scheduled for 5:30 AM PT / 8:30 AM ET SOUTH SAN FRANCISCO, Calif. , Oct. 27, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer,

Oct 15, 2020

Allogene Therapeutics and MD Anderson Announce Strategic Collaboration to Accelerate Advancement of Allogeneic CAR T Therapy (AlloCAR T™)

Clinical and Translational Research Collaboration Will Evaluate Multiple AlloCAR T Candidates Across the Allogene Portfolio Targeting Multiple Tumor Types SOUTH SAN FRANCISCO, Calif. and HOUSTON , Oct. 15, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc.

Oct 01, 2020

Allogene Therapeutics Announces October 2020 Virtual Investor Conference Participation

SOUTH SAN FRANCISCO, Calif. , Oct. 01, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in the Jefferies

Sep 02, 2020

Allogene Therapeutics Announces September 2020 Virtual Investor Conference Participation

SOUTH SAN FRANCISCO, Calif. , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in the following

Aug 05, 2020

Allogene Therapeutics Reports Second Quarter 2020 Financial Results

Initial Phase 1 Results from the ALLO-501 ALPHA Trial at ASCO Demonstrated an Overall Response Rate of 75% and Complete Response Rate of 44% in CAR T Naïve Relapsed/Refractory Non-Hodgkin Lymphoma Patients In the ALPHA Trial, Higher Dose ALLO-647 was Associated with Deeper Lymphodepletion, Delayed

Jul 28, 2020

Allogene Therapeutics to Report Second Quarter 2020 Financial Results on August 5, 2020

Conference Call and Webcast Scheduled for 5:30 AM PT / 8:30 AM ET SOUTH SAN FRANCISCO, Calif. , July 28, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer,

Jul 07, 2020

Allogene Therapeutics Adds Immunotherapy Luminaries, Thomas F. Gajewski, M.D., Ph.D., and Stephan Grupp, M.D., Ph.D., to its Scientific Advisory Board

SOUTH SAN FRANCISCO, Calif. , July 07, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced the appointment of Thomas F.

Jul 01, 2020

Allogene Therapeutics Announces Ton Schumacher, Ph.D., Chair of Scientific Advisory Board, Awarded the Dutch Research Council’s Stevin Prize

Dr. Schumacher Awarded Prestigious Academic Prize in the Netherlands for Research in Cancer Immunotherapy SOUTH SAN FRANCISCO, Calif. , July 01, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics , Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR

Jun 22, 2020

Allogene Therapeutics Presents Preclinical Findings Supporting an Allogeneic DLL3 CAR for Small Cell Lung Cancer and Development of an Inducible TurboCAR™ at the American Association for Cancer Research (AACR) Virtual 2020 Meeting

SOUTH SAN FRANCISCO, Calif. , June 22, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that preclinical findings supporting DLL3-targeted

Jun 22, 2020

Allogene Therapeutics Announces Publication Highlighting Potential for ALLO-819 In Acute Myeloid Leukemia

FLT3-Directed AlloCAR T™ Therapy Demonstrated Potent Anti-Leukemic Activity in Pre-Clinical Models Without Evidence of Off-Target Activity SOUTH SAN FRANCISCO, Calif. , June 22, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 25